This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2017 May 23;317(20):2059-2060.

doi: 10.1001/jama.2017.4316.

FDA Approval of Desmopressin for Nocturia

Michael Fralick¹, Aaron S Kesselheim²

Affiliations

Affiliations

¹ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts2University of Toronto Clinician-Scientist Program, Toronto, Ontario, Canada.
² Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

PMID: 28384655
DOI: 10.1001/jama.2017.4316

FDA Approval of Desmopressin for Nocturia

Michael Fralick et al. JAMA. 2017.

. 2017 May 23;317(20):2059-2060.

doi: 10.1001/jama.2017.4316.

Authors

Michael Fralick¹, Aaron S Kesselheim²

Affiliations

¹ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts2University of Toronto Clinician-Scientist Program, Toronto, Ontario, Canada.
² Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

PMID: 28384655
DOI: 10.1001/jama.2017.4316

No abstract available

PubMed Disclaimer

Comment in

Low-Dose Desmopressin Nasal Spray and FDA Approval.
Fein S, Herschkowitz S. Fein S, et al. JAMA. 2017 Sep 19;318(11):1070-1071. doi: 10.1001/jama.2017.11327. JAMA. 2017. PMID: 28975296 No abstract available.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations